Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS

ZHANG Lu; LU Yanqiu; LIU Dan; HU Jing

doi:10.6039/j.issn.1001-0408.2024.16.14

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS

更新时间：2024-08-23

- Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS
- ZHONGGUO YAOFANG Vol. 35, Issue 16, Pages: 2018-2022(2024)
- 作者机构：
  
  1.重庆市公共卫生医疗救治中心感染科，重庆　400030
  2.陆军军医大学第一附属医院药学部，重庆　400038
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.16.14
  CLC： R978.5
- Published：30 August 2024，
  
  Received：22 April 2024，
  
  Revised：16 July 2024，
- 稿件说明：
扫描看全文
张露,鲁雁秋,刘丹等.两性霉素B联合泊沙康唑治疗艾滋病合并隐球菌性脑膜炎的有效性及安全性 ^Δ[J].中国药房,2024,35(16):2018-2022.

ZHANG Lu,LU Yanqiu,LIU Dan,et al.Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS[J].ZHONGGUO YAOFANG,2024,35(16):2018-2022.
张露,鲁雁秋,刘丹等.两性霉素B联合泊沙康唑治疗艾滋病合并隐球菌性脑膜炎的有效性及安全性 ^Δ[J].中国药房,2024,35(16):2018-2022. DOI： 10.6039/j.issn.1001-0408.2024.16.14.

ZHANG Lu,LU Yanqiu,LIU Dan,et al.Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS[J].ZHONGGUO YAOFANG,2024,35(16):2018-2022. DOI： 10.6039/j.issn.1001-0408.2024.16.14.

摘要

目的

观察两性霉素B联合泊沙康唑治疗艾滋病合并隐球菌性脑膜炎（CM）的有效性和安全性。

方法

回顾性收集2021年1月至2023年6月重庆市公共卫生医疗救治中心、陆军军医大学第一附属医院收治的44例艾滋病合并CM患者资料，根据治疗方案的不同分为两性霉素B联合氟胞嘧啶（AmB+FC）组和两性霉素B联合泊沙康唑（AmB+POS）组，每组各22例。AmB+FC组患者给予注射用两性霉素B+氟胞嘧啶注射液，AmB+POS组患者给予注射用两性霉素B+泊沙康唑注射液。治疗12周后观察两组患者的临床疗效、临床症状、脑脊液隐球菌转阴率，以及治疗前后的实验室检查结果，并记录两组患者的不良反应发生情况。

结果

治疗12周后，两组患者的总有效率，发热、视物模糊发生率以及白细胞减少、贫血、肾功能异常、低钾血症、肝功能异常、皮疹、周围神经病变发生率比较，差异均无统计学意义（

＞0.05）。AmB+POS组患者的脑脊液隐球菌转阴率显著高于AmB+FC组，头痛、恶心呕吐发生率以及任何不良事件发生率均显著低于AmB+FC组（

＜0.05）。两组患者的脑脊液压力、脑脊液蛋白含量均显著低于同组治疗前，脑脊液葡萄糖含量、脑脊液氯化物含量均显著高于同组治疗前（

＜0.05）；但两组间比较，差异均无统计学意义（

＞0.05）。

结论

两性霉素B联合泊沙康唑可提高艾滋病合并CM患者的脑脊液隐球菌转阴率，缓解临床症状，且安全性较好。

Abstract

OBJECTIVE

To observe the efficacy and safety of amphotericin B combined with posaconazole in the treatment of patients with AIDS combined with cryptococcal meningitis （CM）.

METHODS

The data of 44 patients with AIDS combined with CM admitted to Chongqing Public Health Medical Center and the First Affiliated Hospital of Army Military Medical University from January 2021 to June 2023 were collected retrospectively. They were divided into amphotericin B combined with flucytosine （AmB+FC） group and amphotericin B combined with posaconazole （AmB+POS） group according to treatment regimen， with 22 cases in each group. AmB+FC group was given Amphotericin B for injection+Flucytosine injection； AmB+POS group was given Amphotericin B for injection+posaconazole injection. After 12 weeks of treatment， clinical efficacies of two groups， clinical symptoms and the negative coversion rate of cerebrospinal fluid， and laboratory test results before and after treatment were observed in 2 groups， and the occurrence of adverse drug reactions was recorded in 2 groups.

RESULTS

After 12 weeks of treatment， the total effective rate， the incidences of fever， blurred vision， leukopenia， anemia， renal function abnormalities， hypokalemia， liver function abnormalities， rash， and peripheral neuropathy were compared between the two groups， and the differences were not statistically significant （

＞0.05）. The negative coversion rate of cerebrospinal fluid in AmB+POS group was significantly higher than AmB+FC group； the incidences of headache， nausea and vomiting symptoms， and the incidence of any adverse events were significantly lower than AmB+FC group （

＜0.05）. The cerebrospinal fluid pressure and cerebrospinal fluid protein content of the two groups were significantly lower than those before treatment， and the cerebrospinal fluid glucose content and cerebrospinal fluid chloride content were significantly higher than those before treatment （

＜0.05）； however， the differences were not statistically significant between 2 groups

（

＞0.05）.

CONCLUSIONS

Amphotericin B combined with posaconazole improves the negative coversion rate of cerebrospinal fluid and relieves clinical symptoms in patients with AIDS combined with CM with good safety.

关键词

隐球菌脑膜炎人类免疫缺陷病毒两性霉素B泊沙康唑氟胞嘧啶有效性安全性

Keywords

human immunodeficiency virusamphotericin Bposaconazoleflucytosineefficacysafety

references

MCHALE T C，BOULWARE D R，KASIBANTE J，et al. Diagnosis and management of cryptococcal meningitis in HIV-infected adults[J]. Clin Microbiol Rev，2023，36（4）：e0015622.

RAJASINGHAM R，SMITH R M，PARK B J，et al. Global burden of disease of HIV-associated cryptococcal meningitis：an updated analysis[J]. Lancet Infect Dis，2017，17（8）：873-881.

PERFECT J R，DISMUKES W E，DROMER F，et al. Clinical practice guidelines for the management of cryptococcal disease：2010 update by the Infectious Diseases Society of America[J]. Clin Infect Dis，2010，50（3）：291-322.

刘正印，王贵强，朱利平，等. 隐球菌性脑膜炎诊治专家共识[J]. 中华内科杂志，2018，57（5）：317-323.

LIU Z Y，WANG G Q，ZHU L P，et al. Expert consensus on the diagnosis and treatment of cryptococcal meningitis[J]. Chin J Intern Med，2018，57（5）：317-323.

FLORES V G，TOVAR R M，ZALDIVAR P G，et al. Menin-gitis due to cryptococcus neoformans：treatment with posaconazole[J]. Curr HIV Res，2012，10（7）：620-623.

徐云娜. 伏立康唑联合两性霉素B治疗隐球酵母菌性脑膜炎临床疗效观察[J]. 临床医学，2017，37（6）：61-62.

XU Y N. Clinical observation of voriconazole combined with amphotericin B in the treatment of cryptococcal meningitis[J]. Clin Med，2017，37（6）：61-62.

刘加，方文捷，洪南，等. 免疫正常人群隐球菌性脑膜炎临床分析[J]. 中国真菌学杂志，2016，11（2）：99-102.

LIU J，FANG W J，HONG N，et al. The clinical characte-ristics of cryptococcal meningitis in apparently immunocompetent patients[J]. Chin J Mycol，2016，11（2）：99-102.

王文昭，赵瑛，周晖，等. 32例隐球菌脑膜炎的临床特点和治疗[J]. 中国神经免疫学和神经病学杂志，2008，15（4）：316.

WANG W Z，ZHAO Y，ZHOU H，et al. Clinical characte-ristics and treatment of 32 cases of cryptococcal meningitis[J]. Chin J Neuroimmunol Neurol，2008，15（4）：316.

叶珍洁，吴灵洁，张晓颖，等. 泊沙康唑药动学及其治疗药物监测方法研究进展[J]. 药物评价研究，2021，44（1）：222-228.

YE Z J，WU L J，ZHANG X Y，et al. Advances research on pharmacokinetics and therapeutic drug monitoring of posaconazole[J]. Drug Eval Res，2021，44（1）：222-228.

MOORE J N，HEALY J R，KRAFT W K. Pharmacologic and clinical evaluation of posaconazole[J]. Expert Rev Clin Pharmacol，2015，8（3）：321-334.

YANG M，CHENG L，DAI Q，et al. A novel cryptococcal meningitis therapy：the combination of amphotericin B and posaconazole promotes the distribution of amphotericin B in the brain tissue[J]. Biomed Res Int，2020，2020：8878158.

ESPOSITO V，VIGLIETTI R，GARGIULO M，et al. Successful treatment of cryptococcal meningitis with a combination of liposomal amphotericin B，flucytosine and posaconazole：two case reports[J]. In Vivo，2009，23（3）：465-468.

孙建军，卢洪洲. 《艾滋病诊疗指南第三版（2015版）》更新解读[J]. 浙江大学学报（医学版），2015，44（6）：597-602.

SUN J J，LU H Z. Highlights of the Third Edition of Chinese Guidelines for AIDS Diagnosis and Treatment（2015）[J]. J Zhejiang Univ （Med Sci），2015，44（6）：597-602.

SEGAL B H，HERBRECHT R，STEVENS D A，et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases：Mycoses Study Group and European Organization for research and treatment of cancer consensus criteria[J]. Clin Infect Dis，2008，47（5）：674-683.

陈静丹，盛吉芳. 隐球菌性脑膜炎的诊断与治疗[J]. 中国微生态学杂志，2018，30（3）：344-349.

CHEN J D，SHENG J F. Cryptococcal meningitis：diag-nosis and treatment[J]. Chin J Microecol，2018，30（3）：344-349.

杨明. 泊沙康唑增加两性霉素B脑组织浓度治疗隐球菌脑膜炎的药理学作用及机制研究[D]. 重庆：陆军军医大学，2021.

YANG M. Pharmacological effect and mechanism of posaconazole on cryptococcal meningitis by increasing the concentration of amphotericin B in brain tissue[D]. Chongqing：Army Medical University，2021.

BICANIC T，BROUWER A E，MEINTJES G，et al. Relationship of cerebrospinal fluid pressure，fungal burden and outcome in patients with cryptococcal meningitis under-going serial lumbar punctures[J]. AIDS，2009，23（6）：701-706.

PAPPAS P G，CHETCHOTISAKD P，LARSEN R A，et al. A phase Ⅱ randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis[J]. Clin Infect Dis，2009，48（12）：1775-1783.

中华医学会神经病学分会感染性疾病与脑脊液细胞学学组，中国医师协会神经内科医师分会神经感染性疾病专业委员会. 颅内曲霉菌病诊治中国专家共识[J]. 中华神经科杂志，2023，56（7）：729-737.

Infectious Diseases and Cerebrospinal Fluid Cytology Group of Neurology Branch of the Chinese Medical Association, Neurology Infectious Diseases Professional Committee of Neurophysicians Branch of the Chinese Medical Doctor Association. Chinese expert consensus on the diagnosis and management of intracranial aspergillosis[J]. Chin J Neurol，2023，56（7）：729-737.

屠莹，陈丽娟，钱红玉，等. 基于FAERS数据库的泊沙康唑不良事件信号挖掘与分析[J]. 现代药物与临床，2023，38（11）：2861-2866.

TU Y，CHEN L J，QIAN H Y，et al. Signal mining and analysis of posaconazole adverse events based on FAERS database[J]. Drugs Clin，2023，38（11）：2861-2866.

CAPILLA J，FLAVIA A，MAYAYO E，et al. Efficacy of intrathecal liposomal amphotericin B plus oral posacona-zole in the treatment of acute meningeal cryptococcosis in a murine model[J]. Int J Antimicrob Agents，2013，42（3）：282-283.

DERAY G. Amphotericin B nephrotoxicity[J]. J Antimicrob Chemother，2002，49（Suppl. 1）：37-41.

FOLK A，BALTA C，HERMAN H，et al. Flucytosine and amphotericin B coadministration induces dose-related renal injury[J]. Dose Response，2017，15（2）：15593258-17703461.

PASCUAL A，CALANDRA T，BOLAY S，et al. Voricona-zole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J]. Clin Infect Dis，2008，46（2）：201-211.

刘晓东，于丹，菅凌燕. 三氮唑类抗真菌药不良反应的文献分析[J]. 中国新药杂志，2013，22（13）：1591-1594.

LIU X D，YU D，JIAN L Y. The domestic literature analysis of adverse drug reactions caused by triazole antifungal drugs[J]. Chin J N Drugs，2013，22（13）：1591-1594.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of camrelizumab combined with pemetrexed and nedaplatin in the treatment of EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer

Real-world study on piperacillin-tazobactam in the treatment of complicated urinary tract infection in adults

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Efficacy and safety of aerosol inhalation of polycolistin B in patients with severe pneumonia combined with mechanical ventilation

Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer

Related Author

TAN Fengyan

TANG Yiding

MENG Long

SONG Jie

QIU Feng

LONG Rui

YANG Yi

LI Ming

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Chongqing Medical University

School of Pharmacy， Chongqing Medical University

Dept. of Clinical Pharmacy， Zhongjiang County People’s Hospital

Dept. of Pharmacy， the Affiliated Hospital of Guizhou Medical University

Institution of Clinical Drug Trial， the Affiliated Hospital of Guizhou Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰